Sandoz launches the 1st version of multiple sclerosis drugs in US

Sandoz

Sandoz launches the 1st version of multiple sclerosis drugs in US

Novartis International AG/ Sandoz reports US launch of Glatopa(TM), the first generic contender to Copaxone(R) 20mg. Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is only in charge of the content of this declaration.

Glatopa is the first FDA-approved, substitutable generic version of Copaxone(R) 20mg – a treatment for relapsing forms of multiple sclerosis.

Sandoz has started shipping to US clients taking after recent FDA approval. Novartis and Sandoz, together are driving access to a full range of differentiated, high-quality MS therapeutic choices, supplemented by a full range of support services.

Holzkirchen, Germany, June 18, 2015 – Sandoz, a Novartis organization, today announced the US launch of Glatopa(TM), the first generic version of TEVA’s Copaxone(R) (glatiramer acetate injection) 20 mg/ml one-time-day by day multiple sclerosis treatment.

Peter Goldschmidt, President of Sandoz US said that Sandoz, together with Momenta, is glad to declare the US market launch of a completely substitutable generic version of multiple sclerosis drugs, after taking FDA’s approval.

MS is a debilitating disease affecting about a large portion of a million people in the US alone; just 50 per cent of those diagnosed are presently treated.

Glatopa, grew in a joint effort with Momenta and produced entirely in the US, is indicated for the treatment of patients with relapsing forms of MS, including the individuals who have encountered a first clinical episode and have magnetic resonance imaging (MRI) features consistent with MS.

The Sandoz service offering will incorporate financial backers to qualified patients, personalized injection training and 24-hour access to nurses for non-clinical inquiries.

Battling MS, together with different CNS disorders, is integral to the Novartis mission, and Sandoz’s Glatopa joins a wide MS portfolio including two approved therapies and one late-arrange development compound.

Copaxone(R) 20mg is TEVA’s top seller by far, generating $ 4.1 billion sales in the past four quarters. TEVA is declines by 1 per cent after hours on light volume, where as MNTA is up 3 per cent on increased volume.

Christy Gren
Christy Gren is an Industry Specialist Reporter at Industry Leaders Magazine she enjoys writing about Unicorns, Silicon Valley, Startups, Business Leaders and Innovators. Her articles provide an insight about the Power Players in the field of Technology, Auto, Manufacturing, and F&B.

Leave a Reply

Your email address will not be published.

Recent Posts

Tesla Shuts San Mateo Office Laying Off 200 Employees

Tesla Shuts San Mateo Office Laying Off 200 Employees

The billionaire entrepreneur had previously commented on reducing the salaried workforce at Tesla. Out of nearly 100,000 Tesla employees worldwide, 42% are based out of the United
3 hours ago
The Mattel Metaverse – Launched by Cryptoys

The Mattel Metaverse – Launched by Cryptoys

In a recent interview, he acknowledged that toys and players are continuously evolving. Keeping this in mind, the company wants to develop its wares both in the physical and digita
9 hours ago
Multiple Fires Force CPSC to Recall Costco Solar Patio Umbrellas

Multiple Fires Force CPSC to Recall Costco Solar Patio Umbrellas

The Costco umbrella recall was jointly issued by the CPSC, Health Canada, SunVilla, and Costco. The CPSC has urged customers to remove the solar panel puck from the top of the umbr
1 day ago
Volvo Zero-emission Truck – Traced by Water Vapor

Volvo Zero-emission Truck – Traced by Water Vapor

In early 2022, Volvo signed the Drive to Zero pledge, reiterating its commitment to provide zero-emission commercial vehicles. Volvo is one of the largest manufacturers of cars, tr
1 day ago
Bill Ackman on Inflation: The Fed Will Hike Interest Rates

Bill Ackman on Inflation: The Fed Will Hike Interest Rates

Last month, the hedge fund manager suggested that only aggressive monetary tightening or a collapse in the economy will do the trick. He stated that the markets will recover if the
3 days ago
Cadillac’s Luxury Electric Vehicle Starts At $300,000

Cadillac’s Luxury Electric Vehicle Starts At $300,000

The Lyriq is the headliner for Cadillac as it is the first of GM’s brands to go all-electric by 2030.The Celestiq will not roll off GM’s usual factories, rather it will be
3 days ago